Literature DB >> 11096108

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

R L Shields1, A K Namenuk, K Hong, Y G Meng, J Rae, J Briggs, D Xie, J Lai, A Stadlen, B Li, J A Fox, L G Presta.   

Abstract

Immunoglobulin G (IgG) Fc receptors play a critical role in linking IgG antibody-mediated immune responses with cellular effector functions. A high resolution map of the binding site on human IgG1 for human Fc gamma RI, Fc gamma RIIA, Fc gamma RIIB, Fc gamma RIIIA, and FcRn receptors has been determined. A common set of IgG1 residues is involved in binding to all Fc gamma R; Fc gamma RII and Fc gamma RIII also utilize residues outside this common set. In addition to residues which, when altered, abrogated binding to one or more of the receptors, several residues were found that improved binding only to specific receptors or simultaneously improved binding to one type of receptor and reduced binding to another type. Select IgG1 variants with improved binding to Fc gamma RIIIA exhibited up to 100% enhancement in antibody-dependent cell cytotoxicity using human effector cells; these variants included changes at residues not found at the binding interface in the IgG/Fc gamma RIIIA co-crystal structure (Sondermann, P., Huber, R., Oosthuizen, V., and Jacob, U. (2000) Nature 406, 267-273). These engineered antibodies may have important implications for improving antibody therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11096108     DOI: 10.1074/jbc.M009483200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  387 in total

1.  Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.

Authors:  Ralf Kircheis; Nicole Halanek; Iris Koller; Wolfgang Jost; Manfred Schuster; Gilbert Gorr; Klaus Hajszan; Andreas Nechansky
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice.

Authors:  Hans D Brightbill; Surinder Jeet; Zhonghua Lin; Donghong Yan; Meijuan Zhou; Martha Tan; Allen Nguyen; Sherry Yeh; Donnie Delarosa; Steven R Leong; Terence Wong; Yvonne Chen; Mark Ultsch; Elizabeth Luis; Sree Ranjani Ramani; Janet Jackman; Lino Gonzalez; Mark S Dennis; Anan Chuntharapai; Laura DeForge; Y Gloria Meng; Min Xu; Charles Eigenbrot; Wyne P Lee; Canio J Refino; Mercedesz Balazs; Lawren C Wu
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

3.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Authors:  Larry Zeitlin; James Pettitt; Corinne Scully; Natasha Bohorova; Do Kim; Michael Pauly; Andrew Hiatt; Long Ngo; Herta Steinkellner; Kevin J Whaley; Gene G Olinger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 4.  Engineered CD3 antibodies for immunosuppression.

Authors:  L Renders; T Valerius
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

5.  Quantitative evaluation of fucose reducing effects in a humanized antibody on Fcγ receptor binding and antibody-dependent cell-mediated cytotoxicity activities.

Authors:  Shan Chung; Valerie Quarmby; Xiaoying Gao; Yong Ying; Linda Lin; Chae Reed; Chris Fong; Wendy Lau; Zhihua J Qiu; Amy Shen; Martin Vanderlaan; An Song
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 6.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

Review 7.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 8.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 9.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

10.  The decoy Fcγ receptor encoded by the cytomegalovirus UL119-UL118 gene has differential affinity to IgG proteins expressing different GM allotypes.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Faisal F Radwan; Paul J Nietert
Journal:  Hum Immunol       Date:  2015-09-14       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.